2023

Dr McKean on the Rationale For Evaluating LAG-3 Inhibitors in Advanced Melanoma

Meredith McKean, MD, MPH, discusses the rationale for investigating the LAG-3 inhibitor fianlimab in combination with cemiplimab-rwlc in patients with advanced melanoma, highlighting the combination’s efficacy in both PD-1 inhibitor-exposed and –naïve populations, as well as the combinations its potential clinical significance within the advanced melanoma space.

Read More
MRV News
Melanoma News
Archive
Menu